Profile data is unavailable for this security.
About the company
Gubra A/S is a Denmark-based biotechnology company specialized in high-end pre-clinical contract research and peptide-based drug discovery within metabolic and fibrotic diseases. The Company’s operations are anchored around its advanced technology platforms and utilization of automation, robotization and digitalization, including machine learning (ML) and artificial intelligence (AI). The Company's business activity are divided into two segments: The CRO Segment offers specialized profitable pre-clinical contract research services at attractive margins within metabolic and fibrotic disease areas such as diabetes, obesity, chronic kidney disease; and The Discovery and Partnership Segment is based on an internal target and drug discovery engine for identification and design of peptide-based drug partnering candidates within metabolic and fibrotic diseases.
- Revenue in DKK (TTM)205.01m
- Net income in DKK-44.52m
- Incorporated2008
- Employees219.00
- LocationGubra A/SHoersholm Kongevej 11 BHOERSHOLM 2970DenmarkDNK
- Websitehttps://www.gubra.dk/
More ▼
Mergers & acquisitions
| Acquired company | GUBRA:CPH since announced | Transaction value |
|---|---|---|
| MiniGut ApS | 284.09% | -- |
Data delayed at least 15 minutes, as of May 08 2024 16:10 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Egetis Therapeutics AB (publ) | 36.74m | -208.79m | 1.17bn | 27.00 | -- | 3.36 | -- | 31.90 | -1.28 | -1.28 | 0.224 | 1.86 | 0.087 | 16.92 | 3.59 | 2,129,630.00 | -49.44 | -33.02 | -55.92 | -36.46 | 80.87 | -- | -568.00 | -357.72 | 3.32 | -- | 0.1688 | -- | 154.87 | 15.35 | -68.68 | -- | -- | -- |
| Nanoform Finland Oyj | 19.14m | -154.84m | 1.24bn | 165.00 | -- | 2.28 | -- | 64.68 | -0.2674 | -0.2674 | 0.0331 | 0.8535 | 0.0287 | 138.93 | 4.11 | 15,548.42 | -23.22 | -27.13 | -25.12 | -29.48 | -507.09 | -604.26 | -809.08 | -1,023.70 | 8.16 | -- | 0.0964 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Genovis AB | 101.09m | 39.29m | 1.26bn | 37.00 | 32.04 | 10.33 | 27.67 | 12.45 | 0.9394 | 0.9394 | 2.42 | 2.91 | 0.7203 | -- | -- | 4,276,541.00 | 27.99 | 18.56 | 30.74 | 21.45 | 72.20 | 65.51 | 38.87 | 23.88 | -- | -- | 0.2936 | 0.00 | 54.54 | 35.56 | 449.56 | -- | 47.59 | -- |
| Hansa Biopharma AB | 105.98m | -539.79m | 1.29bn | 166.00 | -- | -- | -- | 12.16 | -16.07 | -16.07 | 3.15 | -7.10 | 0.1424 | 64.03 | 1.86 | 987,386.90 | -72.51 | -47.96 | -92.27 | -56.12 | 56.80 | 64.18 | -509.33 | -835.04 | 2.55 | -9.65 | 1.65 | -- | -13.22 | 109.06 | -36.09 | -- | -35.24 | -- |
| Vicore Pharma Holding AB | 66.60m | -136.05m | 1.46bn | 26.00 | -- | 4.67 | -- | 21.92 | -2.15 | -2.15 | 1.01 | 4.38 | 0.2589 | -- | 14.41 | 4,343,459.00 | -52.89 | -58.65 | -59.34 | -65.58 | -- | -- | -204.27 | -- | -- | -- | 0.00 | -- | -- | -- | -7.81 | -- | -- | -- |
| Probi AB | 388.16m | -384.62k | 1.49bn | 167.00 | -- | 1.64 | 24.34 | 3.84 | -0.0528 | -0.0528 | 53.32 | 125.16 | 0.3885 | 3.23 | 6.52 | 3,797,144.00 | -0.0385 | 4.64 | -0.0407 | 4.98 | 32.39 | 42.04 | -0.0991 | 9.83 | 6.22 | -- | 0.0353 | 21.42 | 1.52 | 0.7684 | -58.60 | -26.09 | 31.01 | -- |
| Nykode Therapeutics ASA | 89.22m | -243.09m | 2.92bn | 173.00 | -- | 2.47 | -- | 32.77 | -1.33 | -1.33 | 0.4793 | 5.68 | 0.0601 | -- | 10.14 | 807,247.60 | -16.36 | 5.65 | -19.00 | 6.38 | -- | -- | -272.48 | 18.13 | -- | -- | 0.0324 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Calliditas Therapeutics AB | 771.07m | -297.84m | 4.22bn | 195.00 | -- | 17.76 | -- | 5.47 | -8.69 | -8.69 | 22.49 | 6.24 | 0.6332 | 5.02 | 9.30 | 6,189,175.00 | -24.46 | -26.46 | -30.27 | -30.27 | 94.99 | -- | -38.63 | -76.59 | 3.08 | -4.44 | 0.7427 | -- | 50.32 | -- | -13.08 | -- | -- | -- |
| Surgical Science Sweden AB | 564.05m | 149.48m | 4.76bn | 260.00 | 31.79 | 1.71 | 25.71 | 8.43 | 4.59 | 4.59 | 17.32 | 85.16 | 0.1888 | 1.87 | 6.15 | 3,395,585.00 | 5.00 | 4.49 | 5.31 | 4.78 | 69.42 | 70.06 | 26.50 | 23.75 | 3.56 | -- | 0.00 | 0.00 | 10.01 | 68.14 | 24.47 | -- | 38.57 | -- |
| Gubra A/S | 205.01m | -44.52m | 5.53bn | 219.00 | -- | 11.48 | -- | 26.96 | -2.91 | -2.91 | 13.51 | 29.44 | -- | -- | -- | 936,095.90 | -- | -- | -- | -- | 56.06 | -- | -21.72 | -- | -- | -- | 0.1296 | -- | 2.82 | -- | -1,133.04 | -- | -- | -- |
| Swedencare AB (publ) | 1.54bn | 45.68m | 5.53bn | 552.00 | 121.10 | 1.12 | 22.58 | 3.59 | 0.4505 | 0.4505 | 15.21 | 48.80 | 0.2412 | 2.35 | 9.52 | 4,966,461.00 | 0.7144 | 1.38 | 0.7361 | 1.43 | 55.64 | 55.34 | 2.96 | 5.10 | 1.82 | 2.21 | 0.1746 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 830.87m | 237.19m | 7.76bn | 211.00 | 33.95 | 5.81 | 30.68 | 9.34 | 3.68 | 3.68 | 12.88 | 21.47 | 0.5414 | -- | -- | 6,192,767.00 | 15.46 | 15.47 | 16.82 | 16.93 | 73.32 | 73.30 | 28.55 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| AddLife AB | 6.26bn | 50.47m | 8.15bn | 2.29k | 166.90 | 2.55 | 12.52 | 1.30 | 0.6483 | 0.6483 | 80.41 | 42.38 | 0.7393 | 3.62 | 5.53 | 4,258,149.00 | 0.6112 | 5.31 | 0.9299 | 8.83 | 37.16 | 36.89 | 0.8267 | 5.79 | 0.4778 | 1.48 | 0.5173 | 31.73 | 6.62 | 31.30 | -60.42 | 8.00 | 44.43 | -1.89 |
Data as of May 08 2024. Currency figures normalised to Gubra A/S's reporting currency: Danish Krone DKK
12.10%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 1.03m | 6.31% |
| Danske Bank A/S (Investment Management)as of 29 Feb 2024 | 710.83k | 4.35% |
| Deka Investment GmbHas of 31 Oct 2023 | 86.11k | 0.53% |
| Schroder Investment Management Ltd.as of 30 Jun 2023 | 60.00k | 0.37% |
| Schroder Investment Management (Europe) SA (Finland)as of 31 Jan 2024 | 50.00k | 0.31% |
| Cicero Fonder ABas of 30 Apr 2024 | 20.00k | 0.12% |
| E. �hman J :or Fonder ABas of 29 Feb 2024 | 9.73k | 0.06% |
| J.O. Hambro Capital Management Ltd.as of 30 Apr 2024 | 9.02k | 0.06% |
| Sydbank A/S (Investment Management)as of 30 Apr 2024 | 1.94k | 0.01% |
More ▼
Data from 31 Dec 2023 - 30 Apr 2024Source: FactSet Research Systems Inc.
